Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

NCT01994473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856
DRUG: Placebo
DRUG: SEP-363856 Open Label

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.